If we accept that follicular lymphoma remains an incurable disease, (with the exception of the few cases which are possibly cured with bone marrow transplantation) then the purpose of treatment is prolongation of survival and optimisation of the quality of life.
Treatments which have shown to prolong survival are those involving the immune system: Interferon alpha, rituximab and allogeneic transplantation.
If Interferon could show its survival-increasing capacity only when associated to first-line chemotherapy, both rituximab and allo-transplant can obtain this lifeprolonging effect also when used in second or further lines. For rituximab this is true both when given together with chemotherapy and when given as a maintenance. It follows that what is important for an FL patient is that he receives rituximab, independently of chemotherapy. We can even say that it was demonstrated that one needs rituximab on top of chemotherapy but we are still not sure that we need chemotherapy on top of rituximab.
Nowadays the median overall survival of follicular lymphoma has risen from 10 to approximately 15 years. It becomes therefore more and more true that FL patients live a long time and are exposed, as Hodgkin's lymphoma patients, to the potential longterm side effects of chemotherapy. Delaying chemotherapy is therefore a way of ameliorating quality of life both by postponing the acute and the long-term side effects of cytotoxic treatment.
A recent study by the BNLI could very well show that single-agent rituximab can postpone the initiation of chemotherapy by several years.
In conclusion we believe that patients with follicular lymphoma will sooner or later need chemotherapy, but that many of them, if not in need of a very rapid response, a course of single agent rituximab followed by rituximab maintenance gives a chance of conserving a good quality of life while delaying the side-effects of chemotherapy, all without losing any survival advantage. This forthcoming debate deals with the battle between ''cold'' and ''hot'' antibodies in first remission follicular NHL or -to be more precise -Rituximab-maintenance for a prolonged period of time versus a single infusion of a radio-labelled anti-CD20 monoclonal antibody. Only a few large randomized trials with newly diagnosed patients with follicular NHL have been reported recently. From my perspective, the core of the debate focuses on the comparative evaluation of the ECOG 1496 study and the FIT trial. In the ECOG study newly diagnosed patients with indolent (mainly follicular) lymphoma were induced with CVP and responders were subsequently randomized between Rmaintenance, once per week for 4 weeks every 6 months x4 (1); in the FIT trial various chemo-induction regimens were allowed after which PR and CR patients were randomized between one infusion of Zevalin versus no further treatment (2). Obviously, there was pronounced hematological toxicity in the FIT trial, which was -howevermanageable. No patients died from toxicity. CR rates after induction were 16% (ECOG) versus 52% (FIT), increasing to 37% (ECOG) and 87% (FIT), due to 22% and 78%, respectively, of patients in PR converting to CR. With more than 4 yrs (ECOG) and 6.5 yrs (FIT; 3) median follow-up, the median PFS was prolonged by 3 years in both studies as compared to controls. In patients achieving a CR after Zevalin, the PFS increased more than 5 years as compared to controls (median PFS > 92 months after 1 infusion of Zevalin. . ..). This has never been shown before with any other single agent. Thus, a single infusion of Zevalin matched roughly 4 x 4 = 16 infusions of Rituximab in terms of achieving the same increase in PFS. I leave it up to the audience to draw conclusions about cost-effectiveness . . .
As the FIT trial was initiated in 2001, only a relatively small fraction of the patients (14%) was induced with R-chemo. Thus, the question arises whether Zevalin is effective after R-chemo induction as this is standard treatment to date. To this end, it was observed that 71% of the R-chemo patients converted from PR to CR after Zevalin and showed a longer PFS as compared to controls. Similar conversion rates were reported from phase II studies in which Zevalin consolidation was given after R-chemo induction. These observations, and others to be presented, make it quite likely that Zevalin works after R-chemo as long as there are accessible CD20-positive targets.
Thus, in conclusion, RIT represents the most effective single ''drug'' in the treatment of follicular NHL. No doubt about it.
Finally, in this context results of the less mature PRIMA trial will be discussed and a proposal will be put forward on how ''cold'' and ''hot'' might fight side-to-side in defeating follicular NHL. Rituximab has become part of first-line treatment in most patients with follicular lymphoma as several prospective trials have shown benefits both in progression-free survival (PFS) as well as in overall survival compared to chemotherapy alone. Also the use of rituximab as maintenance has shown benefits in several trials with a consistent marked prolongation of PFS with minimal toxicity. This benefit has occurred whether maintenance follows single-agent rituximab or combination chemotherapy. A randomized clinical trial comparing induction therapy with single-agent rituximab 375 mg/m(2) once per week x 4, versus the same induction followed by one infusion of maintenance every 2 months x4, showed that 45% of the patients responding to the induction were still event-free at 8 years with prolonged exposure to rituximab (Martinelli et al JCO 2010) .
Patients with relapsed/resistant FL responding to CHOP or R-CHOP induction have a superior PFS with rituximab maintenance, confirmed also after a median follow-up of 6 years (van Oers et al JCO 2010) .
According to the results of the large intergroup ''Primary Rituximab and Maintenance'' [PRIMA] trial, maintenance with rituximab during 2 years improves PFS significantly in pts with previously untreated FL responding to
